ORMP - Oramed Pharmaceuticals Inc.
After hours:
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.0200 |
| Open | 3.9900 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1200 |
| Day's Range | 3.9500 - 4.2001 |
| 52 Week Range | 1.8100 - 13.7300 |
| Volume | |
| Avg. Volume | 970,052 |
| Market Cap | 161.711M |
| Beta (5Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8100 |
| Earnings Date | Nov 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.77 |
Fair Value
Related Research
Zacks Small Cap ResearchORMP: Advancing Development Efforts in China
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Licensing deal – potential royalty payments if product is commercialized in China … Earlier this month, Oramed Pharmaceuticals’ (NASDAQ:ORMP) partner in China, Hefei Tianhui Biotechnology Co. (HTIT), completed a Phase 3 oral insulin clinical trial in China and, based on the results, submitted a marketing authorization application to
PR NewswireOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed's oral delivery technology as well as insights from the Company's recent Phase 3 oral insulin clinical trials.
PR NewswireOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a strategic partner of Oramed, has successfully completed its Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol. HTIT is now moving toward regulatory approval and has submitted the data to the National Medical Products Administration (NMPA, formerly the CFDA).
BloombergConservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company
(Bloomberg) -- Right-wing media entrepreneur Ben Shapiro has taken a $4.7 million stake in a struggling Israeli pharmaceutical company and joined the board.Most Read from BloombergNigeria Targeted a UK Mansion; Its Next Leader’s Son Now Owns ItWall Street Rattled by 15% Tumble in Pair of Banks: Markets WrapCarl Icahn’s Wealth Plunges $10 Billion on Hindenburg Short-Seller ReportIBM to Pause Hiring for Jobs That AI Could DoRegional Bank Shares Plunge on Fear of More Rescues to ComeShapiro, 39, a
- PR Newswire
Oramed Appoints Ben Shapiro to its Board of Directors
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.
Simply Wall St.The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- PR Newswire
Oramed Pharmaceuticals Issues Shareholder Update
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company's existing pipeline and conducting a comprehensive review of strategic alternatives focused on enhancing shareholder value.
Zacks Small Cap ResearchORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals’ (NASDAQ:ORMP) recently released top-line results from its ORA-D-013-1 Phase 3 study comparing the efficacy of ORMD-0801 to placebo in patients with T2D (type 2 diabetes) at 26 weeks failed to meet primary and secondary endpoints. Oramed expects to discontinue its oral insulin clinical activities for T2D. This
Motley FoolWhy Oramed Pharmaceuticals Stock Is Crashing Today
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
BenzingaOramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from
- PR Newswire
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering ag
- Simply Wall St.
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- PR Newswire
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceu
- PR Newswire
Oramed Letter to Shareholders
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
- ACCESSWIRE
Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022
The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.
- PR Newswire
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: "Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study," authored by Roy Eldor, MD PhD, Bruce H. Francis, MD, Alexander Fleming, MD, Joel Neutel, MD, Kenneth Homer, MS, Miri
Zacks Small Cap ResearchORMP: Data from NASH Phase 2 Study – Positive Takeaways
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Data supports moving ahead with NASH clinical studies… Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has multiple clinical development programs underway. ORMD-0801, ORMP’s lead development candidate, is being tested in diabetes in dual concurrent Phase 3 studies of ORMD-0801 for the treatment of T2D and in NASH. We believe Oramed’s multiple
BenzingaOramed Pharma Shares Fall After Additional Data From Oral Insulin Study
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has announced additional data from its Phase 2 trial (ORA-D-N02) of oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH). Overall, the Phase 2 trial proved that ORMD-0801 might be a potential candidate for reducing liver fat, stiffness, and lipids in patients with T2D and NASH. Related: Oramed Oral Insulin Shows Evidence For NASH Treatment. The whole Liver showed a placebo-ad
- PR Newswire
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced additional positive data from its Phase 2 double-blind, fully randomized, placebo-controlled, multicenter clinical trial (ORA-D-N02) to assess the safety and efficacy of its oral insulin candidate (ORMD-0801), to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis ("NASH"). The presentation
- Simply Wall St.
Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Oramed Pharmaceuticals ( NASDAQ:ORMP ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.06m (loss...
- PR Newswire
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has signed an exclusive commercial distribution agreement for the Republic of Korea (formerly South Korea) with Medicox Co., Ltd., an emerging biotech company with an excellent consortium of proven partnerships in the Republic of Korea.
- PR Newswire
Oramed Reports Third Quarter 2022 Financial Results
Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter ended September 30, 2022.
- PR Newswire
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes ("T2D") patients with non-alcoholic steatohepatitis ("NASH") on Thursday, November 17, 2022, at 11:00 a.m. Eastern St
- Simply Wall St.
Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years
While Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) shareholders are probably generally happy, the stock hasn't had...
BenzingaOramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study
Oramed Pharmaceuticals Inc's (NASDAQ: ORMP) subsidiary, Oravax Medical Inc, reported preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in most patients dosed. No safety issues were observed, including mild symptoms. An open-label, Phase 1 trial will evaluate the safe